Vaishali Pharma Limited

VAISHALI

INE972X01014

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:56 2024-07-04 EDT			5-day change	1st Jan Change
168.6 ^INR	+9.25%		+6.25%	-7.34%

05-30	Vaishali Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
02-02	Vaishali Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Vaishali Pharma Limited Appoints Hemant Pathak as Chief Executive Officer

May 26, 2020 at 05:06 am

Vaishali Pharma Limited at its Meeting held on 26 May, 2020 has appointed Mr. Hemant Pathak as Chief Executive Officer of the Company with effect from 26 May 2020.

Latest news about Vaishali Pharma Limited

Vaishali Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-30	CI
Vaishali Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-02	CI
Vaishali Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-08	CI
Vaishali Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-07	CI
Vaishali Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-22	CI
Vaishali Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-06	CI
Vaishali Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-03	CI
Vaishali Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-07-25	CI
Vaishali Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022	22-05-30	CI
Vaishali Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-01-21	CI
Vaishali Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-10	CI
Vaishali Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	21-07-24	CI
Vaishali Pharma Limited Receives Supply Orders in Excess of USD 100,000 from Russia	21-06-21	CI
Vaishali Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	21-05-14	CI
Vaishali Pharma Limited Receives an Order Worth USD 270,000	21-04-22	CI
Vaishali Pharma Limited Initiates 30 Products Registration in Central African Countries	21-04-15	CI
Vaishali Pharma Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	21-01-19	CI
Vaishali Pharma Limited Receives Another Bulk Order Worth INR 320 Million of PPE KITS	21-01-13	CI
Vaishali Pharma Limited Enters into In-Licensing Agreement for the U.S.A Market	21-01-03	CI
Vaishali Pharma Limited Provides Updates on the Major Bulk Order of INR 160 Million for PPE Kits & Covid -19 Medical Kits	21-01-01	CI
Vaishali Pharma : Secures over $2 Million Bulk Order for PPEs and COVID-19 Related Products; Shares Soar 10%	20-12-30	MT
Vaishali Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	20-09-15	CI
1,325,000 Equity Shares of Vaishali Pharma Limited are subject to a Lock-Up Agreement Ending on 31-AUG-2020.	20-08-30	CI
Vaishali Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2020	20-07-30	CI
Vaishali Pharma Launches Vipravita C (Immunity Booster Vitamin C Supplements)	20-07-14	CI

Vaishali Pharma Limited is an India-based pharmaceutical company. The Company is engaged in dealing in pharmaceutical ingredient, pharmaceutical formulations, surgical products, herbal and nutraceutical products, veterinary supplements operating in domestic and export market. Its product categories include active pharmaceutical ingredients (APIs), formulation brands, formulations, herbal, nutraceuticals, oncology, surgical and veterinary, among others. It offers APIs, including antibiotics, anti-ulcer, anti-inflammatory/analgesic/anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, anti-diarrheal/anti-protozoal/anti-parasitic, anti-viral, anti-epileptic, anti-asthmatic, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helmintic drugs, as well as excipients, topical steroids, corticosteroids, and enzymes. The Company markets approximately 1,500 products and has more than 200 brands, around 35 countries.

Sector

Pharmaceuticals

Calendar

2024-07-21 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VAISHALI PHARMA LIMITED	-7.34%	19.81M
ELI LILLY AND COMPANY	+54.07%	809B
NOVO NORDISK A/S	+38.95%	621B
JOHNSON & JOHNSON	-7.05%	351B
MERCK & CO., INC.	+15.44%	319B
ABBVIE INC.	+5.72%	289B
ASTRAZENECA PLC	+14.21%	238B
ROCHE HOLDING AG	-0.45%	221B
NOVARTIS AG	+14.58%	218B
AMGEN INC.	+7.42%	166B